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Abstract 
Background: Fused in sarcoma (FUS) is an RNA-binding protein associated with the neurodegenerative diseases 
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration. ALS manifests in patients as a progressive 
paralysis which leads to respiratory dysfunction and failure, the primary cause of death in ALS. We expressed human 
FUS in rats to determine if FUS would induce ALS relevant respiratory changes to serve as an early stage disease indi-
cator. The FUS expression was initiated in adult rats by way of an intravenously administered adeno-associated virus 
vector serotype 9 (AAV9) providing an adult onset model.
Results: The rats developed progressive motor impairments observed as early as 2–3 weeks post gene transfer. 
Respiratory abnormalities manifested 4–7 weeks post gene transfer including increased respiratory frequency and 
decreased tidal volume. Rats with breathing abnormalities also had arterial blood acidosis. Similar detailed plethys-
mographic changes were found in adult rats injected with AAV9 TDP-43. FUS gene transfer to adult rats yielded a 
consistent pre-clinical model with relevant motor paralysis in the early to middle stages and respiratory dysfunction at 
the end stage. Both FUS and TDP-43 yielded a similar consistent disease state.
Conclusions: This modeling method yields disease relevant motor and respiratory changes in adult rats. The repro-
ducibility of the data supports the use of this method to study other disease related genes and their combinations as 
well as a platform for disease modifying interventional strategies.
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Background
Amyotrophic lateral sclerosis (ALS) is a neurodegenera-
tive disease affecting upper and lower motor neurons. 
The disease causes a progressive paralysis including 
paralysis of the diaphragm and other respiratory mus-
cles. Respiratory complications and failure are the most 
common cause of death in ALS [1, 2]. Prior to respira-
tory failure, ALS patients exhibit breathing abnormalities 
including hypercapnia [partial pressure of carbon diox-
ide (pCO2) >40 mmHg] and hypoxemia [partial pressure 
of oxygen (pO2) <80  mmHg] [3, 4] as well as increased 
respiratory frequency and decreased tidal volume [5]. 
Disease relevant respiratory abnormalities have been 
demonstrated in a mutant form of copper, zinc super-
oxide dismutase 1 (mSOD1) mouse model [6], and a rat 
model of mSOD1 exhibited decreased motor output 
from the phrenic nerve [7, 8]. In humans, a variety of 
genetic etiologies can result in ALS and here we studied 
breathing in a model based on the RNA-binding protein 
fused in sarcoma/translocated in liposarcoma (FUS). We 
studied breathing parameters with a sensitive plethys-
mography system in a rat model. The main goal was to 
study breathing changes induced by FUS in an effort to 
establish a sensitive early disease physiological marker 
for detecting either the efficacy of therapeutic inter-
vention or potentiation of the disease state by disease 
modulators.
FUS is an RNA- and DNA-binding protein that reg-
ulates transcription, alternative splicing, and mRNA 
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transport [9]. FUS shares homology and some overlap 
in function with the RNA-binding protein transactive 
response DNA-binding protein of 43  kDa (TDP-43). 
Both proteins are associated with ALS and the related 
disease frontotemporal lobar degeneration (FTLD) [10–
20] in terms of causative mutations and neuropathology 
(proteinopathy). Wild-type FUS is found aggregated in 
FTLD with FUS-positive inclusions (FTLD-FUS) [17–
19] and has also been found in pathological aggregates 
in sporadic ALS [21]. Mutations of other RNA-homeo-
stasis proteins are also associated with ALS, including 
TATA-binding protein associated factor 15 (TAF15) [22, 
23] and Ewing’s sarcoma breakpoint region 1 (EWSR1) 
[24], which further underscores the importance of 
RNA metabolism in underlying disease mechanisms. 
We have previously established rat models of progres-
sive paralysis by expressing TDP-43 [25–27]. Here we 
expressed FUS in rats, in order to test the hypothesis 
that another ALS related RNA-binding protein would 
exert a similar disease state, presumably by interference 
of normal RNA metabolism. Overexpression of wild-
type FUS has been shown to be toxic in yeast [28–30] 
and drosophila [31], and a variety of rodent models have 
been developed using either mutant or wild-type FUS, 
both forms showing evidence of motor impairments 
and ALS-like pathology [32–35]. We used a novel and 
unique viral vector expression system in adult rats to 
study respiratory changes. Rat physiological parameters 
such as heart rate and breathing are closer to humans 
than mice, so rats are therefore advantageous to study 
breathing parameters.
The adeno-associated virus (AAV) vector system is 
an advantageous method to control the onset of expres-
sion within specific neuronal populations. AAV9 can 
be delivered intravenously in rats to yield wide-scale 
expression in the central nervous system (CNS) includ-
ing efficient transduction of spinal motor neurons 
necessary for motor performance [25]. When TDP-
43 was expressed in this manner, a highly consistent 
motor phenotype developed over time [25]. The first 
study used neonatal rats which provide very efficient 
gene transfer [25]. However, we recently adapted the 
approach to adult subjects which are more relevant to 
adult onset diseases such as ALS and FTLD [26]. Here 
we administered adult rats with AAV9 FUS and studied 
motor and respiratory parameters over time, including 
analysis of blood pH and blood gas content. We tested 
if the motor and respiratory sequelae would arise con-
comitantly or if one sequela would precede the other. 
Plethysmography was also studied in AAV9 TDP-43 
transduced rats for the first time to address if a simi-
lar phenotype was induced by the two disease-related 
RNA-binding proteins.
Results
FUS‑induced disease state: decreased weight and motor 
impairments
To examine the effects of FUS gene transfer in adult 
rats, three groups were examined: (1) AAV9 FUS 
(human wild-type); (2) AAV9 green fluorescent pro-
tein (GFP); and (3) vehicle-only controls. The animals 
were weighed just before gene transfer and weekly up to 
8  weeks (Fig.  1a). There was a significant effect of time 
on weight gain (two-way repeated measures analysis of 
variance (RM ANOVA), F4,48  =  232.20, p  <  0.0001) as 
expected. There was a trend for an effect of  treatment 
group (F2,12 = 12, p = 0.065), and there was a significant 
interaction between time post-injection and treatment 
group on weight (F8,48  =  7.58, p  <  0.0001), suggest-
ing some differences in weight gain between treatment 
groups over time. For example, at the time points of 3 
and 4 weeks, the FUS group weighed less than the vehicle 
and GFP groups (Bonferroni post-test, p < 0.01 and 0.05, 
respectively).
To determine if rats administered AAV9 FUS devel-
oped motor impairments, animals were evaluated by 
rotarod, escape reflex, locomotor activity chamber, and 
forelimb grip strength. There were no differences found 
between the vehicle and GFP control groups on any of 
these measurements. On rotarod there was a signifi-
cant effect of treatment group (two-way RM ANOVA, 
F2,12 = 4.36, p < 0.05) indicating that FUS affected rotarod 
ability. There was a significant effect of time on rotarod 
performance (F4,48 = 13.97, p < 0.0001), as we have pre-
viously observed in young to middle age rats [25]. There 
was a significant interaction between treatment group 
over time (F8,48  =  5.58, p  <  0.0001) indicating that the 
FUS rats exhibited progressively impaired rotarod abil-
ity over this period. The FUS group showed significant 
rotarod deficits compared to the vehicle group at 3 and 
4 weeks post-injection (Bonferroni post-test, p < 0.01 and 
0.001, respectively) and at 4  weeks post-injection com-
pared to GFP animals (Bonferroni post-test, p  <  0.01; 
Fig. 1B). For the escape reflex, all of the vehicle and GFP 
animals retained hindlimb extension when lifted by the 
tail whereas all of the FUS animals developed an abnor-
mal hindlimb clenching (Mantel-Cox log-rank test, 
p < 0.01; Fig. 1C). Hindlimb clasping is an indicator of a 
lesion in the motor pathway [36]. However, in the loco-
motor testing, there were no significant effects of FUS 
gene transfer on rearing or distance traveled in this study 
using this vector dose and interval (data not shown). 
Forelimb grip strength in the FUS group was significantly 
decreased compared to both vehicle and GFP animals at 
4  weeks post-injection (analysis of variance (ANOVA)/
Bonferroni, p < 0.001; Fig. 1D). These motor tests suggest 
that gross motor function and coordination (as measured 
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by rotarod) in rats administered AAV9 FUS are impaired 
due to both dysfunctional hindlimbs (hindlimb clench-
ing) and forelimbs (decreased forelimb grip strength).
FUS‑induced disease state: plethysmographic changes
Using unrestrained whole-body plethysmography, respir-
atory frequency, tidal volume, minute ventilation, inspira-
tory time, expiratory time, and total respiratory time were 
measured weekly throughout the study (Fig. 2). Between 
weeks 4 and 8 post-injection, FUS animals began to dis-
play progressive breathing impairments characterized by 
rapid, shallow breathing patterns (Fig.  2). The last ple-
thysmography session before death or euthanasia was 
considered “end stage” which varied from 4 to 8  weeks 
depending on the individual animal treated with AAV9 
FUS or AAV9 TDP-43. Due to this range of onset times, 
we compared the baseline to the end stage of disease 
progression in the FUS and TDP-43 animals. Vehicle 
and GFP control rats were not affected in this manner, so 
baseline was compared with 8 weeks post-injection in the 
controls. For respiratory frequency, there were signifi-
cant effects of vector and time as well as an interaction 
between the two (two-way RM ANOVA, F2,12  =  38.48, 
p  <  0.0001; F1,12  =  22.18, p  <  0.001; F2,12  =  41.94, 
p < 0.0001, respectively). There was no difference in vehi-
cle or GFP control rats between time points; however, 
FUS rats developed significantly increased respiratory 
frequency at end stage (Fig.  3b; two-way RM ANOVA/
Bonferroni, p  <  0.01). Tidal volume represents the lung 
volume of air displaced with normal inhalation and exha-
lation in the absence of any extra effort and is then nor-
malized to body weight. There was a significant effect of 
vector as well as an interaction between vector and time 
(two-way RM ANOVA, F2,12 = 4.45, p < 0.05; F2,12 = 8.54, 
Fig. 1 FUS gene transfer causes progressive motor impairments. A There was an indication of lowered weight gain in FUS rats by ANOVA (see 
“Results”). The FUS group weighed significantly less than the vehicle and GFP groups at 3 and 4 weeks post-injection (p < 0.05–0.01). B FUS rats 
were significantly impaired for rotarod performance by ANOVA with significant differences found at 1, 3, or 4 weeks compared to the vehicle group 
(p < 0.05–0.001) and at 4 weeks compared to the GFP group (p < 0.01). C All of the FUS rats developed hindlimb clenching during the escape reflex 
while no vehicle or GFP rats showed abnormal hindlimb clenching during the study (p < 0.01). D The FUS group had decreased forelimb strength at 
4 weeks compared to both vehicle and GFP (p < 0.001). There were no significant differences between the vehicle and GFP groups in any of these 
measures. “a”, significant difference between FUS and vehicle groups; “b”, significant difference between FUS and GFP (ANOVA/Bonferroni post-tests 
in A, B, D and Mantel-Cox log rank analysis in C; n = 4–6/group as indicated)
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p < 0.005, respectively). There was no difference between 
pre-injection and 8 weeks in vehicle or GFP control rats, 
but tidal volume was significantly decreased at end stage 
in the FUS rats (Fig.  3c; two-way RM ANOVA/Bonfer-
roni, p  <  0.01). Minute ventilation is the volume of air 
displaced over one minute and is the product of respira-
tory frequency and tidal volume, normalized to body 
weight. There was a significant effect of vector, a trend for 
significance of time, and an interaction between vector 
and time (two-way RM ANOVA, F2,12 =  7.30, p  <  0.01; 
F1,12 = 4.40, p = 0.058; F2,12 = 7.18, p < 0.01). Minute ven-
tilation at end stage in FUS rats was increased (Fig.  3d, 
two-way RM ANOVA/Bonferroni, p = 0.01). For inspira-
tory time, there was a significant effect of vector and time 
as well as an interaction between the two (two-way RM 
ANOVA, F2,12 = 22.24, p < 0.0001; F1,12 = 10.45, p < 0.01; 
F2,12  =  61.35, p  <  0.0001, respectively). For expiratory 
time, there was a significant effect of vector, a trend for 
significance of time, and an interaction between vector 
and time (two-way RM ANOVA, F2,12 = 75.85, p < 0.0001; 
F1,12 = 4.35, p = 0.059; F2,12 = 54.41, p < 0.0001, respec-
tively). Total time, as expected, had significant effects of 
vector and time and an interaction between vector and 
time (two-way RM ANOVA, F2,12  =  88.61, p  <  0.0001; 
F1,12 = 9.12, p < 0.05; F2,12 = 80.79, p < 0.0001). Inspira-
tory, expiratory, and total times all showed small but 
significant increases from pre-injection to 8 weeks for the 
vehicle group (Fig. 3e–g, two-way RM ANOVA/Bonfer-
roni, p < 0.05, 0.01, 0.01, respectively). This could suggest 
acclimation to the testing chamber. Furthermore, it is not 
uncommon to observe normal changes in motor per-
formance over time in controls [26].  However, this pat-
tern was reversed in FUS rats which exhibited decreased 
inspiratory and expiratory time (Fig. 3e–g, two-way RM 
ANOVA/Bonferroni, p  <  0.01 and 0.001, respectively), 
indicating impairment of normal respiration due to FUS. 
The breathing abnormalities at end stage were clearly vis-
ible in the home cage as rapid, pulsatile hyperventilation. 
TDP-43, another RNA-binding protein implicated 
in ALS and RNA homeostasis, was tested for effects on 
plethysmography in a similar manner. Four animals were 
administered AAV9 TDP-43, which all developed simi-
lar breathing changes as the FUS group above. At end 
stage, measurements from TDP-43 animals indicated 
elevated respiratory frequency [233  ±  37 breaths per 
minute (bpm)], reduced tidal volume (1.86 ± 0.28 ml/kg), 
and increased minute ventilation (431 ± 55 ml/min/kg), 
decreased inspiratory time (152.6 ± 37.4 ms), decreased 
expiratory time (128.1  ±  18.9  ms), and decreased total 
respiratory time (280.1  ±  43.0  ms). We did not record 
pre-injection baseline for the TDP-43 rats. We com-
pared the end stage values from the TDP-43 rats with 
Fig. 2 Changes in respiratory parameters in FUS rats over time. Respiratory parameters studied include respiratory frequency (a), tidal volume (b), 
minute ventilation (c), inspiratory time (d), expiratory time (e), and total respiratory time (f). Each FUS rat is displayed as a separate black line, and the 
average values ± SEM of vehicle and GFP animals are shown in orange and green respectively
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the 8 week time point values from the two control groups 
(vehicle and GFP) by ANOVA/Bonferroni. The TDP-43 
rats showed significantly increased respiratory frequency, 
reduced tidal volume, increased minute ventilation, and 
decreased inspiratory time, expiratory time, and total 
respiratory time compared to the controls (p  <  0.05–
0.0001). When comparing the TDP-43 group to the FUS 
group at the end stage, there was a similar amplitude of 
effect of FUS as TDP-43 gene transfer on respiration.
Hypoxemia and acidosis accompany rapid breathing
Due to the tachypnea seen in diseased rats, arterial pH 
and blood gases were evaluated at end stage as a meas-
ure of cardiopulmonary function in a small subset of ani-
mals (Table 1). Though preliminary, there appeared to be 
similar changes in both the FUS and TDP-43 animals for 
the blood parameters measured. In the FUS and TDP-43 
animals, blood pH was below 7.35, indicating acido-
sis, whereas none of the vehicle or GFP animals showed 
blood pH < 7.35. The blood pH of the FUS animals was 
significantly lower than the vehicle animals even with this 
small cohort size (ANOVA/Bonferroni, p < 0.05), and the 
blood pH of the TDP-43 animals was significantly lower 
than either the vehicle or GFP groups (p < 0.01). Some of 
the FUS and TDP-43 animals also exhibited abnormally 
low blood oxygen saturation (<90%). The FUS and TDP-
43 animals had significantly lower oxygen saturation 
levels than either the vehicle or GFP groups (ANOVA/
Bonferroni, p  <  0.05, p  <  0.001, respectively for both 
FUS and TDP-43). The FUS animals showed below nor-
mal pO2 (<70 mmHg) though not statistically significant, 
and the TDP-43 animals had statistically decreased pO2 
(ANOVA/Bonferroni, p < 0.01). pCO2 appeared elevated 
relative to normal values (>50  mmHg) in some of the 
Fig. 3 Rapid, shallow breathing in AAV9 FUS rats at end stage. a Representative plethysmography tracings of 5 s of respiration in a FUS rat at pre-
injection and end stage (week 0 and week 5). b Respiratory frequency was increased in the FUS group at end stage (p < 0.001). c Tidal volume was 
decreased in FUS rats at end stage (p < 0.01). d Minute ventilation was significantly increased at end stage in FUS rats (p < 0.01). e The vehicle group 
showed increased inspiratory time over 8 weeks (p < 0.05); whereas, the FUS group showed decreased inspiratory time at end stage (p < 0.001). 
f Expiratory time was increased in the vehicle group after 8 weeks (p < 0.01) and decreased in the FUS group (p < 0.001). g Total respiratory time 
was increased in the vehicle group (p < 0.05) and decreased in the FUS group (p < 0.001). The n in b–g is 4–6/group as indicated in b. Asterisk 
indicates p < 0.05
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FUS and TDP-43 animals though these measurements 
were not statistically different than controls. In contrast 
to FUS and TDP-43, GFP gene transfer did not alter 
blood pH, oxygen saturation, or pO2 relative to the vehi-
cle group.
FUS and GFP transgene expression
We confirmed expression of FUS from the FUS DNA 
construct in transfected cells (Fig.  4a). The construct 
expresses an untagged form of human FUS. Using a FUS 
antibody that recognizes both rat and human FUS, we 
were unable to clearly detect up-regulated FUS expres-
sion in western blot samples of spinal cord, nor did we 
observe clearly increased immunohistochemical staining 
in the FUS animals. Thus, we can conclude that the level 
of FUS overexpression was subtle, below a several fold 
overexpression. We know that less than two-fold over-
expression of TDP-43 in the spinal cord is sufficient to 
induce paralysis [37], so it is not surprising that low level 
FUS overexpression could induce the phenotype.
We have previously characterized the transgene 
expression pattern from AAV9 gene delivery to adult 
rats with this promoter construct, which incorporates 
the cytomegalovirus/chicken beta-actin promoter and 
the woodchuck hepatitis virus post-transcriptional regu-
latory element (WPRE) [27]. In the CNS, we can expect 
relatively robust expression in the spinal motor neurons, 
cerebellar Purkinje cells, and dorsal root ganglia neurons. 
The transgenes are also expressed in the liver, heart, and 
muscle in this system. We believe that expression in the 
spinal cord is essential for the motor deficits because 
we have experimented with a promoter that expresses 
TDP-43 in liver but not the spinal cord, which does not 
produce the paralysis (unpublished). Furthermore, we 
know that if we apply AAV9 TDP-43 (with the the hybrid 
cytomegalovirus/chicken β-actin (CBA) promoter as 
in this study) into the cerebral ventricles, we observe 
motor paralysis (unpublished), so we believe the motor 
deficits are mediated in the CNS. In contrast to FUS, 
the GFP in the AAV9 GFP group was easier to detect 
(Fig.  4b–d), presumably due to the lack of the endog-
enous protein and better signal-to-noise  ratio. GFP was 
expressed in lumbar spinal motor neurons. There was 
co-localization of GFP and SMI 311 immunoreactivity 
(non-phosphorylated neurofilament), which labels motor 
neurons (Fig. 4b–d).
Discussion
These data establish a relevant and consistent disease 
modeling system in rats based on intravenous FUS 
gene transfer for the first time. FUS exerted disease 
relevant symptoms with an adult onset, at a small fold-
overexpression (less than twofold) in the spinal cord. 
This adult model is relevant to adult onset diseases, like 
ALS, and provides an experimental system that is far 
more amenable to pre-treatment baseline data collec-
tion as well as different interventional schedules com-
pared to modeling systems in which the FUS expression 
begins earlier in development [33]. The FUS gene 
transfer produced progressive paralysis and decreased 
grip strength in adult rats. Plethysmographic analyses 
revealed rapid, shallow breathing in the FUS rats at the 
end stage of the disease state which was characterized 
by dramatic increases in respiratory frequency coupled 
with significant decreases in tidal volume. Although 
minute ventilation is the product of respiratory fre-
quency and tidal volume, significant minute ventilation 
changes were observed due to the degree of increase in 
respiratory frequency. This breathing pattern can lead 
to hypercapnia due to ineffective gas exchange related 
to increased dead space. Consistent with the theory of 
inefficient gas exchange, there was arterial blood aci-
dosis and decreases in pO2 and O2 saturation indica-
tive of either pulmonary or diaphragmatic dysfunction. 
However, it is also possible that the hypoxia could have 
precipitated the rapid breathing. Hyperventilatory 
responses to hypoxia are mediated by chemoreceptor 
reflexes of oxygen-sensing cells in the carotid bodies 
which activate peripheral axons of petrosal ganglion 
neurons [38, 39]. These petrosal neurons project to the 
nucleus of the solitary tract in the brainstem [40, 41] 
which integrates and transmits afferent chemosensory 
activity to respiratory neurons that regulate respiratory 
rate and volume. In addition to affecting spinal cord 
motor neurons which innervate the diaphragm, there 
are a few cases suggesting that ALS-related neuro-
degeneration may also progress to involve brainstem 
nuclei that control the integration and processing of 
Table 1 Arterial blood pH and gases
Data for 4 GFP rats, 6 vehicle rats, 2 FUS rats, and 2 TDP-43 rats
GFP (n = 4) Vehicle (n = 6) FUS 1 FUS 2 TDP‑43 1 TDP‑43 2
pH 7.38 ± 0.02 7.38 ± 0.01 6.95 7.34 7.18 7.31
pO2 (mmHg) 74 ± 3.9 77 ± 9.5 61 69 43 44
sO2 (%) 94.25 ± 1.26 94.33 ± 1.75 78 92 65 74
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respiratory signals which could lead to deleterious 
breathing irregularities [42, 43].
We observed transgene expression in spinal motor 
neurons in this study, but we can only hypothesize that 
FUS expression in spinal motor neurons is what underlies 
the breathing changes. We attempted to evaluate phrenic 
motor neuron survival at the C4 region of the spinal cord 
to determine if the respiratory abnormalities seen were 
mediated in part by a loss of phrenic motor neurons, but 
we were limited due to technical issues. In addition to 
motor neurons, the effect could be mediated in the res-
piratory centers in the medulla or at the diaphragm mus-
cle. More refinement of the expression pattern by altering 
the promoter, the type of AAV, as well as the  route of 
administration could better pinpoint the site of action. 
Engineered AAVs will be advantageous to achieve better 
transduction efficiencies and better targeting, for exam-
ple, AAV-PHP.B [44].
We anticipated that the breathing measurements, due 
to their precise quantitative features, would provide a 
sensitive, early stage marker and detect subtle changes, 
but the breathing changes were severe and arose consist-
ently after the onset of the limb paresis/paralysis. How-
ever, we were able to closely and quantitatively monitor 
the onset of end stage in the FUS animals using plethys-
mography, in essence pinpointing the final stage in pro-
gression to death. Motor and respiratory deficits induced 
by FUS are relevant to ALS, and plethysmography offers 
a precise physiological readout to study treatments that 
may either delay or block the progression to end stage or 
conversely accelerate the time to end stage.
Respiratory failure and complications is the most com-
mon cause of death in ALS, and respiratory ability is a 
predictive factor in survival [45–47]. Patients with ALS 
typically develop respiratory problems after the onset of 
paralysis, although in rare cases respiratory impairments 
can be the presenting symptom [48]. The FUS rats fol-
lowed the typical human sequence with motor abnormal-
ities developing earlier than the respiratory abnormalities 
which appeared at the end stage. It is worth noting that 
the rapid, shallow breathing seen in the FUS rats mimics 
reports of ALS patients with decreased tidal volumes and 
increased respiratory frequency [5]. Interestingly, some 
similar relevant changes in breathing were also found 
in mSOD1 transgenic mice such as decreased tidal vol-
ume, although the mSOD1 mice developed slower res-
piratory frequency [6]. Rats at end stage in this model 
showed blood acidosis which is relevant to both human 
ALS and the mSOD1 mouse model. Blood acidosis seen 
in ALS patients has been shown to be related to poorer 
prognosis [46], and transgenic mSOD1 mice show acido-
sis in the end and moribund stages of disease [49]. Drugs 
that inhibit carbonic anhydrase, which regulates blood 
Fig. 4 FUS and GFP transgene expression. a Transfection of the FUS 
DNA construct resulted in FUS overexpression in HEK293T cells at the 
expected molecular weight. b AAV9 GFP expression in the lumbar 
spinal cord of a rat that received AAV9 GFP 8 weeks earlier. GFP 
immunofluorescent staining is in b, SMI 311, a motor neuron marker 
antibody immunofluorescence is in c, and the merger is in d. The 
co-localization indicates GFP expression in motor neurons. Bar in d is 
134 μm
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pH, have been shown to accelerate disease progression 
in mSOD1 mice [49]. This indicates that acidosis is not 
only a biomarker but also a potential contributor to the 
progression of disease. Since blood pH was only evalu-
ated at end stage, we were unable to determine if acidosis 
preceded the respiratory dysfunction. An interesting next 
step would be a long-term catheter for longitudinal blood 
pH and blood gas readings to test if the hypoxia precedes 
the rapid breathing. However, the catheter could cer-
tainly affect motor function [50].
Conclusions
Adult rats administered AAV9 FUS develop a consist-
ent and ALS-relevant disease state including progressive 
motor paralysis and respiratory dysfunction. Since both 
RNA-binding proteins FUS and TDP-43 caused similar 
changes in motor function [27] and respiratory function, 
we hypothesize that both proteins exert similar or partial 
overlapping dysfunctions in RNA metabolism [51] that 
underlie the disease states. Plethysmography provided a 
precise monitoring of progressive changes in breathing 
parameters in FUS rats that are relevant to ALS and other 
ALS models. The relevant and consistent motor and 
respiratory symptoms may provide a useful pre-clinical 
model for therapeutic development as well as for study-
ing underlying disease processes.
Methods
AAV vector production
The vector cassette was composed of AAV serotype 2 
inverted terminal repeats, the hybrid cytomegalovirus/
chicken β-actin promotor, a GFP, FUS, or TDP-43 con-
struct, the woodchuck hepatitis virus post-transcriptional 
regulatory element (WPRE), and the bovine growth hor-
mone polyadenylation sequence [52]. The vector cassette 
was packaged into AAV9 using helper and capsid plas-
mids from the University of Pennsylvania [53, 54]. All 
vectors were prepared under the same laboratory condi-
tions. Viral stocks were sterilized via Millipore Millex-
GV syringe filter (Billerica, MA), titered by dot blot assay, 
aliquoted, and stored frozen until use.
Animals
Six to seven-week old female Sprague–Dawley rats (Har-
lan, Indianapolis, IN) were administered either AAV9 
FUS (n = 8) at a dose of 3 × 1013 vector genomes (vg)/kg, 
AAV9 TDP-43 (n = 4) at a dose of 3 × 1013 vg/kg, AAV9 
GFP (n = 4) at a dose of 3 × 1013 vg/kg to control for the 
expression of a foreign transgene, or 200 μl lactated Ring-
er’s solution (n = 6) as a vehicle control. Two of the TDP-
43 rats were simultaneously co-administered AAV9 GFP 
at a dose of 2  ×  1013 vg/kg. Female rats were used for 
consistency of measurements and lower and more stable 
body weights. Lower weights allow for less viral vector to 
be administered on a per kg basis, and more stable body 
weights helped ensure consistency of motor and lung 
function analyses. Estrus cycle was not controlled for in 
this study although some reports have shown increased 
respiratory frequency in the diestrus phase [55]. For vec-
tor administration, viral vectors were diluted to 200 μl in 
lactated Ringer’s solution and drawn up in a 1 ml syringe 
attached to a 30 gauge needle. Rats were anesthetized 
with isoflurane and placed on a heating pad. Their tails 
were swabbed with alcohol to better visualize the tail 
veins, and vector or vehicle was slowly administered to 
the lateral tail vein. Rats were allowed to recover from 
anesthesia before being returned to their cage. Weight 
and general health were monitored weekly. All animal 
procedures followed protocols approved by the insti-
tutional Animal Care and Use Committee and National 
Institutes of Health Guide for the Care and Use of Labo-
ratory Animals. End stage euthanasia criteria included 
body weight less than 87.5% of the expected value and 
signs of pain including hunched posture, lethargy, por-
phyrin staining, decreased grooming, visibly increased 
respiratory frequency, or vocalization when touched. 
Three of eight animals injected with the AAV9 FUS failed 
to manifest breathing abnormalities by 8 weeks and only 
showed partial motor deficits relative to the other five 
rats in this group. We believe the less severe phenotype 
in these three animals was due to technical variability 
and for that reason they were not included in the data 
analysis.
Rotarod
Rotarod (Rota-rod/RS, Letica Scientific Instruments, 
Barcelona, Spain) was conducted before injections (base-
line) and then weekly for seven weeks following the injec-
tions. The rats were allowed to acclimate to the room for 
30 min before testing began. Testing consisted of meas-
uring the amount of time the rats can remain walking 
on the rotarod before falling off (latency to fall). The rod 
accelerated from 4 to 40 revolutions per minute (RPM) 
over 2 min, and the average of three trials was taken for 
each animal at each time point.
Locomotor behavior
Locomotor analyses were conducted using a photobeam 
activity monitoring system from Coulbourn Instruments 
(TruScan 2.0, Whitehall, PA). The rats were allowed to 
acclimate to a dark room for 30 min before testing began. 
Tests were conducted for 30  min in the dark. Distance 
traveled and rearing were analyzed at baseline and weekly 
thereafter.
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Grip strength
Forelimb grip strength was analyzed at week 4 post-injec-
tion using a wire mesh attached to a 1 kg hanging scale 
(American Weight Scales, Inc., Norcross, GA). The scale 
was zeroed in the horizontal direction, and the rat’s fore-
limbs were placed in the middle of the mesh. The rat was 
pulled by the tail until it released the mesh. The average 
of three trials was taken for each rat.
Escape reflex
Weekly, animals were lifted briefly by the tail three times 
and extension of the hindlimbs was observed. Hindlimb 
dysfunction was recorded only if the hindlimbs were 
clenched on all three trials.
Plethysmography
Unanesthetized Sprague–Dawley rats were placed in 
an airtight unrestrained, whole-body plethysmograph 
chamber (Buxco rat chamber with Halcyon technol-
ogy, Data Sciences International, St. Paul, MN, USA) 
outfitted with a digital video camera for simultane-
ous behavioral monitoring. While in the chamber, 
rats breathed normoxic (21% O2) room air that was 
continually exchanged at a constant flow rate. A sen-
sitive very low differential pressure transducer (Vali-
dyne DP45; Northridge, CA, USA) connected to the 
chamber converted pressure changes associated with 
inspiration and expiration into respiratory waveforms. 
Integrated temperature and humidity probes were 
used to monitor and compensate for changes in the 
ambient conditions of the chamber. For each experi-
ment, rats were allowed to acclimate in the chamber 
for ~15  min or until behavior stabilized, and then 
respiratory activity and video were simultaneously 
recorded and subsequently analyzed using Ponemah 
software (Data Sciences International, St. Paul, MN, 
USA) to measure tidal volume (ml), minute ventilation 
(ml/min), respiratory frequency (breaths per minute), 
inspiratory time, expiratory time, and total respira-
tory time. Respiratory parameters were averaged from 
≥5 measurements per recording session, obtained by 
sampling 15–20 consecutive breaths every 3  min for 
15–30 min. Tidal volume and minute ventilation were 
normalized to the animal’s weight to compensate for 
potential differences due to animal size. Rats were 
first recorded prior to injection to obtain baseline 
measurements and then weekly thereafter to monitor 
changes in respiratory physiology during disease pro-
gression. To control for potential effects of circadian 
rhythms, all rats were recorded during the light cycle 
and the order in which the rats were tested was varied 
weekly.
Arterial blood collection and analysis
Rats were anesthetized with thiobutabarbital sodium 
(100  mg/kg) injected intraperitoneally. The femoral 
artery was cannulated for arterial blood gases analysis. 
The syringe used to draw the blood was coated in heparin 
(1000 USP units/mL) to prevent blood clotting. Approxi-
mately 0.3  ml of arterial blood from the femoral artery 
was removed and analyzed with an ABL5 blood gas ana-
lyzer (Radiometer Copenhagen, Brea, CA). Rats were 
euthanized immediately after arterial blood collection.
Western blot
HEK293T cells were transfected with 2  μg of the FUS 
DNA construct or 2  μg of a DNA construct without a 
transgene via the calcium chloride method. Cells were 
collected after two days. The samples were sonicated 
in radioimmunoprecipitation assay (RIPA) buffer [1% 
nonidet-P40, 0.5% sodium deoxycholate, 0.1% sodium 
dodecyl sulfate (SDS), phosphate buffered saline (PBS)] 
with ethylenediamine tetraacetic acid (EDTA) and pro-
tease inhibitors (Pierce, Rockford, IL) and centrifuged. 
The supernatant was collected and protein content was 
determined by Bio-Rad Protein Assay Dye. Samples were 
normalized for protein content and electrophoresed in a 
4–12% gradient polyacrylamide gel containing SDS (Bio-
Rad). The primary antibody was anti-FUS (Abcam, Cam-
bridge, MA), the goat anti-mouse secondary antibody 
was from Santa Cruz (Dallas, TX), and ECL reagents 
were from Amersham (Buckinghamshire, UK).
Immunofluorescent staining
While anesthetized, animals were euthanized, and the 
spinal cord was dissected and post-fixed in 4% paraform-
aldehyde overnight at 4°C. Tissues were then transferred 
to 30% sucrose for cryopreservation. 50  μm sections of 
the spinal cord were cut using a sliding microtome with 
a freezing stage. Primary antibodies included anti-GFP 
(Invitrogen) and SMI 311 monoclonal antibody (Cov-
ance) at dilutions of 1:250 and 1:2000, respectively. Sec-
ondary antibodies included Alexa Fluor 488 and Alexa 
Fluor 594 (Invitrogen) at dilutions of 1:300.
Statistical analyses
Statistical analyses were performed on GraphPad Prism 
5.0. Statistical tests included two-way RM ANOVA with 
Bonferroni multiple comparison post-tests, one-way 
ANOVA with Bonferroni multiple comparison post-tests, 
and Mantel-Cox log-rank test as indicated. For all two-
way RM ANOVAs, the within-subject factor (repeated 
measure) is time and the between subject factor is vector 
treatment. Data are expressed as mean ± standard error 
of the mean (SEM).
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